Practical Review of Role and Usage of Corticosteroids in Modern Neuro-Oncology Care.

Authors

Christine Lu-Emerson, Chris Lee, Megan E H Still, Ashley P Ghiaseddin, Mina Lobbous, Surabhi Ranjan, Akanksha Sharma, Nestor Galvez-Jimenez, Rachel S F Moor, Sylvia C Kurz, Denise Leung, Megan Nicole Thomas, Matthew Smith-Cohn, Edina Komlodi-Pasztor, Elizabeth Coffee, David Schiff, Joshua Amit Budhu, Katherine B Peters

Published in

Neurology. Clinical practice. Volume 16. Issue 6. Pages e200679. Epub Oct 16, 2026.

Abstract

Corticosteroids are commonly used in the treatment of neuro-oncology patients. Unfortunately, the benefits of steroids must be balanced against the potential development of complications. This review provides guidance for the usage of steroids in the management of neuro-oncology patients.
Steroids should only be used as a temporizing measure in brain tumor patients to minimize symptoms secondary to mass effect from the tumor. For instance, because of the long half-life of corticosteroids, dosing should be limited to daily or twice per day, with the second dose given no later than early afternoon. Owing to its effects on multiple organ systems including endocrine, dermatologic, immunologic, gastrointestinal, orthopedic, and neuropsychiatric, prolonged steroid use can increase patient morbidity. They can also directly alter the potency of cancer-directed therapy including immunotherapy and chemoradiation. Steroid-sparing options, including bevacizumab, have emerged as means to minimize toxicity. Finally, the effects of steroid on tumor response has been formally integrated into imaging response assessment.
Corticosteroids are an integral and useful treatment of neuro-oncology patients. We recommend using the lowest effective dose, with its frequency limited to 1 to 2 times per day and to taper them off as soon as possible to minimize toxicity and morbidity. The use of corticosteroids in clinical practice warrants specific consideration in the setting of immunotherapy and with assessments of imaging response.

PMID:
42886883
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.